APGE Apogee Therapeutics, Inc.
FY2025 10-K
Apogee Therapeutics, Inc. (APGE) filed its fiscal year 2025 10-K annual report with the SEC on Mar 2, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Clinical-stage biotech developing breakthrough therapeutics focused on protein modulation and drug candidates
- • Emphasis on zumilokibart (APG777) with $76.4M R&D spend in 2025, up $27.2M YoY, reflecting clinical trial expansion and manufacturing scale-up
Management Discussion & Analysis
- • No revenue or profitability figures disclosed for fiscal year 2026 due to clinical-stage status
- • Pipeline focus on four antibody programs targeting inflammatory and immunology diseases, no segment financials given
Financial SummaryXBRL
Net Income
-$256M
Total Assets
$937M
EPS (Diluted)
$-4.22
Operating Cash Flow
-$227M
Source: XBRL data from Apogee Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Apogee Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.